Home › Therapeutic areas › Dermatology
Dermatology (37 companies · 20 conditions)
Conditions
Atopic Dermatitis 14 Psoriasis 8 Hidradenitis Suppurativa 7 Rare Alopecia Areata 3 Acne 2 Netherton Syndrome 2 Rare Onychomycosis 2 Recessive Dystrophic Epidermolysis Bullosa 2 Rare Androgenetic Alopecia 1 Common Wart 1 Gorlin Syndrome 1 Rare Junctional Epidermolysis Bullosa 1 Rare Lichen Planus 1 Lymphatic Malformation 1 Rare Molluscum Contagiosum 1 Peeling Skin Syndrome 1 Rare Pemphigus 1 Rare PIK3CA-Related Overgrowth Spectrum 1 Rare Rosacea 1 Vitiligo 1
Companies
| Ticker | Company | Therapeutic areas | In Dermatology | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| AARD | Aardvark Therapeutics | DermatologyMetabolic+1 Rare | 1 | Phase 3 | $25.2M | 3 |
| ABSI | Absci | DermatologyGI/Hepatology+1 | 1 | Phase 1 | $1.31B | 6 |
| ACRS | Aclaris Therapeutics | DermatologyGI/Hepatology+1 Rare | 4 | Phase 2 | $536M | 7 |
| ALDX | Aldeyra Therapeutics | DermatologyOncology+1 | 1 | NDA Submitted | $41.9M | 5 |
| ALMS | Alumis | DermatologyImmunology+1 | 1 | Phase 3 | $628M | 5 |
| ANAB | AnaptysBio | DermatologyGI/Hepatology+2 Rare | 1 | Approved | $1.36B | 9 |
| APGE | Apogee Therapeutics | DermatologyGI/Hepatology+1 Rare | 3 | Phase 2 | — | 9 |
| RCUS | Arcus Biosciences | DermatologyImmunology+1 | 1 | Phase 3 | $2.36B | 8 |
| BCRX | Biocryst Pharmaceuticals | DermatologyImmunology+1 Rare | 1 | Approved | $1.93B | 4 |
| CABA | Cabaletta Bio | DermatologyImmunology+2 Rare | 1 | Phase 2 | $220M | 8 |
| CLDX | Celldex Therapeutics | DermatologyImmunology+1 | 1 | Phase 3 | $2.20B | 6 |
| CRVS | Corvus Pharmaceuticals | DermatologyOncology+1 Rare | 2 | Phase 3 | $858M | 7 |
| ELOX | Eloxx Pharmaceuticals | DermatologyRenal Rare | 2 | Phase 2 | $48.0M | 4 |
| ENTA | Enanta Pharmaceuticals | DermatologyImmunology+2 | 1 | Approved | $253M | 8 |
| EVMN | Evommune | DermatologyImmunology+1 | 1 | Phase 2 | $290M | 6 |
| FBRX | Forte Biosciences | DermatologyGI/Hepatology | 2 | Phase 2 | — | 3 |
| FBIO | Fortress Biotech | DermatologyHematology+4 Rare | 3 | Approved | $61.4M | 16 |
| IMCR | Immunocore | DermatologyInfectious Disease+2 | 1 | Approved | $1.44B | 12 |
| INMB | Inmune Bio | Dermatology Rare | 1 | Phase 3 | $29.7M | 1 |
| KYMR | Kymera Therapeutics | DermatologyImmunology+1 Rare | 2 | Phase 2 | $10.4B | 5 |
| GLUE | Monte Rosa Therapeutics | CardiovascularDermatology+3 Rare | 1 | Phase 2 | $775M | 7 |
| MLTX | MoonLake Immunotherapeutics | DermatologyImmunology Rare | 1 | NDA Submitted | $957M | 4 |
| NKTR | Nektar Therapeutics | DermatologyImmunology+2 | 2 | Phase 3 | $1.23B | 11 |
| ORKA | Oruka Therapeutics | DermatologyImmunology Rare | 4 | Phase 2 | $6.53B | 7 |
| PTGX | Protagonist Therapeutics | DermatologyHematology+2 Rare | 2 | Approved | $8.14B | 12 |
| TARA | Protara Therapeutics | DermatologyMetabolic+1 Rare | 1 | Phase 3 | $143M | 3 |
| QTTB | Q32 Bio | Dermatology | 1 | Phase 2 | $258M | 3 |
| QNRX | Quoin Pharmaceuticals | DermatologyImmunology Rare | 2 | Phase 2 | $236M | 4 |
| RLAY | Relay Therapeutics | DermatologyOncology Rare | 1 | Approved | $3.64B | 4 |
| RVPH | Reviva Pharmaceuticals | CardiovascularDermatology+3 Rare | 1 | Phase 3 | $4.7M | 11 |
| SGMT | Sagimet Biosciences | DermatologyMetabolic | 2 | Phase 3 | $709M | 3 |
| SYRE | Spyre Therapeutics | DermatologyImmunology Rare | 1 | Phase 2 | $8.91B | 10 |
| TTRX | Turn Therapeutics | DermatologyInfectious Disease Rare | 3 | Phase 2 | $261M | 4 |
| VNDA | Vanda Pharmaceuticals | CardiovascularDermatology+6 Rare | 4 | Approved | $230M | 27 |
| VRCA | Verrica Pharmaceuticals | DermatologyOncology Rare | 3 | Approved | $53.9M | 4 |
| ZBIO | Zenas BioPharma | DermatologyImmunology+2 Rare | 1 | NDA Submitted | $1.88B | 11 |
| ZURA | Zura Bio | DermatologyImmunology Rare | 1 | Phase 2 | $99.7M | 4 |
No companies match.